New sedative ciprofol aims to cut heart injury after lung surgery
NCT ID NCT07028593
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether ciprofol, a newer sedative, can reduce heart injury after lung surgery compared to the standard drug propofol. About 1,058 adults aged 45–80 having video-assisted lung surgery will be randomly assigned to receive one of the two drugs during anesthesia. The main goal is to see if ciprofol lowers the rate of heart muscle damage in the days after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ciprofol (also known as HSK3486)
What this could lead to
If ciprofol works better than propofol, it could become a safer sedative for surgery, lowering the risk of heart damage after lung operations.
What could go wrong
This is a Phase 4 trial, but it only looks at one type of surgery and one complication. Results may not apply to other surgeries or patients, and ciprofol might not prove superior.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji hospital
RECRUITINGWuhan, China
Contact
Contact